Trump’s return puts Medicaid on the chopping block

Sid­dhartha Mukher­jee is some­thing of a biotech Re­nais­sance man. First and fore­most, he sees him­self as an on­col­o­gist. But that core in­ter­est has led him

The FDA will in­creas­ing­ly use ac­cel­er­at­ed ap­proval for gene ther­a­pies aimed at rare con­di­tions, ac­cord­ing to Pe­ter Marks, the FDA’s top of­fi­cial over­see­ing cell and